Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.
The investment comes days after GemPharmatech, which has a similar business model, secured a RMB400 million ($58.6 million) Series B led by GL Ventures, the VC arm of Hillhouse Capital. Biocytogen's...
China Ping An Insurance Overseas Holdings has aspirations to manage assets for third-party investors. Spinning out part of the global private equity portfolio may help it get there
Buoyed by strong macro fundamentals and robust returns, Japan’s buyout managers continue to attract capital while most other strategies across Asia struggle. Will this popularity be sustained?
Zhenkunhang, a China-based distribution platform for industrial products, has raised $315 million Series E funding led by YF Capital - previously Yunfeng Capital - a private equity firm co-founded by Alibaba’s Jack Ma.
Japanese logistics technology start-up Openlogi has raised JPY1.7 billion ($16.7 million) in an ongoing Series C round featuring Sumitomo Corporation.